Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald
In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $19.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Kluska is a 5-star analyst with an average return of 24.4% and a 46.75% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Disc Medicine, DBV Technologies SA – American, and Soleno Therapeutics.
Eupraxia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $15.22.
Based on Eupraxia Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$8.76 million. In comparison, last year the company had a GAAP net loss of C$5.94 million
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.
Read More on TSE:EPRX:
Disclaimer & DisclosureReport an Issue
- Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness
- Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact
- Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00
- Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline
- Eupraxia Pharmaceuticals Plans Public Offering to Fund GI Drug Pipeline
